Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Applied Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: APLT), will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. The event's webcast can be accessed via the company's Investor Relations page. Applied Therapeutics focuses on developing novel drug candidates for high unmet medical needs, notably with three Phase 3 programs in progress, including lead drug AT-007 for rare CNS diseases and AT-001 for Diabetic Cardiomyopathy.

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 11:20 a.m. ET.

Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. Applied Therapeutics’ portfolio includes three Phase 3 programs for diseases with high unmet medical need and no approved treatment options. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia and SORD Deficiency. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx. A copy of the Company’s January 2022 Corporate Presentation is posted to the Investor Relations section of Applied Therapeutics’ website.

Contacts

Investors:
Maeve Conneighton, Eric Kasper
(212) 600-1902 or
appliedtherapeutics@argotpartners.com

Media:
media@appliedtherapeutics.com

FAQ

When will Applied Therapeutics present at the SVB Leerink Global Healthcare Conference?

Applied Therapeutics will present on February 18, 2022, at 11:20 a.m. ET.

Where can I watch the Applied Therapeutics conference presentation?

The presentation will be available as a webcast on the Investor Relations section of the Applied Therapeutics website.

What is the primary focus of Applied Therapeutics?

Applied Therapeutics develops novel drug candidates targeting high unmet medical needs, including treatments for rare CNS diseases and Diabetic Cardiomyopathy.

What are the lead drug candidates of Applied Therapeutics?

The lead drug candidates include AT-007 for CNS rare metabolic diseases and AT-001 for Diabetic Cardiomyopathy.